Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers

5Citations
Citations of this article
77Readers
Mendeley users who have this article in their library.

Abstract

An effective post-exposure prophylaxis (PEP) strategy may limit the spread of infection. However, there is no consensus regarding PEP for Middle East respiratory syndrome coronavirus (MERS-CoV) infection. This study assessed the efficacy of ribavirin and lopinavir/ritonavir as PEP for healthcare workers (HCWs) exposed to patients with severe MERS-CoV pre-isolation pneumonia. The safety of the PEP regimen was assessed. HCWs with high-risk exposure to MERS-CoV pre-isolation pneumonia were retrospectively enrolled. HCWs who received PEP therapy were classified into the PEP group. PEP therapy was associated with a 40% decrease in the risk of infection. There were no severe adverse events during PEP therapy.

Cite

CITATION STYLE

APA

Park, S. Y., Lee, J. S., Son, J. S., Ko, J. H., Peck, K. R., Jung, Y., … Shi, H. (2019). Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. Journal of Hospital Infection, 101(1), 42–46. https://doi.org/10.1016/j.jhin.2018.09.005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free